HIV-1 exploits Hes-1 expression during pre-existing HPV-16 infection for cancer progression
- 8 February 2023
- journal article
- research article
- Published by Springer Nature in VirusDisease
- Vol. 34 (1) , 29-38
Abstract
High Risk Human Papilloma Viruses (HR-HPV) persistently infect women with Human Immunodeficiency Virus-1 (HIV-1). HPV-16 escapes immune surveillance in HIV-1 positive women receiving combined antiretroviral therapy (cART). HIV-1 Tat and HPV E6/E7 proteins exploit Notch signaling. Notch-1, a developmentally conserved protein, influences cell fate from birth to death. Notch-1 and its downstream targets, Hes-1 and Hey-1 contribute to invasive and aggressive cancers. Cervical cancer cells utilize Notch-1 and hyper-express CXCR4, a co-receptor of HIV-1. Accumulating evidence shows that HIV-1 affects cell cycle progression in pre-existing HPV infection. Additionally, Tat binds Notch-1 receptor for activation and influences cell proliferation. Oncogenic viruses may interfere or converge together to favor tumor growth. The molecular dialogue during HIV-1/HPV-16+ co-infections in the context of Notch-1 signaling has not been explored thus far. This in vitro study was designed with cell lines (HPV-ve C33A and HPV-16+ CaSki) which were transfected with plasmids (pLEGFPN1 encoding HIV-1 Tat and pNL4-3 encoding HIV-1 [full HIV-1 genome]). HIV-1 Tat and HIV-1 inhibited Notch-1expression, with differential effects on EGFR. Notch-1 inhibition nullified Cyclin D expression with p21 induction and increased G2-M cell population in CaSki cells. On the contrary, HIV-1 infection shuts down p21 expression through interaction of Notch-1 downstream genes Hes-1-EGFR and Cyclin D for G2-M arrest, DDR response and cancer progression. This work lays foundations for future research and interventions, and therefore is necessary. Our results describe for the first time how HIV-1 Tat cancers have an aggressive nature due to the interplay between Notch-1 and EGFR signaling. Notch-1 inhibitor, DAPT used in organ cancer treatment may help rescue HIV-1 induced cancers. Graphical abstract The illustration shows how HIV interacts with HPV-16 to induce Notch 1 suppression for cancer progression (Created with BioRender.com).Keywords
Funding Information
- Indian Council of Medical Research (5/2-3/LDCE/2015-ECD-II)
This publication has 35 references indexed in Scilit:
- Impact of Tat Genetic Variation on HIV-1 DiseaseAdvances in Virology, 2012
- Early human papillomavirus testing predicts residual/recurrent disease after LEEPJournal of Gynecologic Oncology, 2012
- Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemiaCell Cycle, 2011
- Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell linesLeukemia Research, 2009
- Cross-Talk Between Notch and EGFR Signaling in Human Breast Cancer CellsCancer Investigation, 2009
- Cell-cycle and suppressor proteins expression in uterine cervix in HIV/HPV co-infection: comparative study by tissue micro-array (TMA)BMC Cancer, 2008
- Notch-1 regulates transcription of the epidermal growth factor receptor through p53Carcinogenesis, 2008
- The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesisCancer Biology & Therapy, 2006
- HPV16 E6 and E7 oncoproteins regulate Notch‐1 expression and cooperate to induce transformationJournal of Cellular Physiology, 2003
- Induction of Cyclin D1 Transcription and CDK2 Activity by Notch ic : Implication for Cell Cycle Disruption in Transformation by Notch icMolecular and Cellular Biology, 2001